This is the news I have been waiting for!
We have a great company here,well established and proven superiority,
and now going international. The share price should skyrocket over
the next year, I will be holding long for the next few major moves.
Way to go Peter Evans and staff

This is the news I have been waiting for!
We have a great company here,well established and proven superiority,
and now going international. The share price should skyrocket over
the next year, I will be holding long for the next few major moves.
Way to go Peter Evans and staff

Time to move up to Extract One!
Thank you Doug777 for that find. The sooner the public are aware of their
option to upgrade to a much safer and more efficient security system, the better off we all will be. I am sure this will take time, but the testing results are clearly in favor of Extract One. It is shameful how Evolv has attempted to hide results in an effort to hang on to their clients, at the expense of safety and putting lives at risk. I believe it is just a matter of time for Extract One to begin replacing the old magnetic
detectors. Who can trust a security company that is so deceptive as Evolv?
Our CEO has integrity and honesty, and is leading us to a safer place.

I am in the same boat sorry to say
I called my direct investing advisors who said it sometimes takes
3 or 4 days, when I told them it was over a week the advised me
to phone the company which I did. Could only leave a message
and no reply. Not sure what else to do as it is needed data

See through bookbags, give me a break !
Xtract One also sees through the stuff in the bag, detects dangerous goods,
but more importantly maintains the dignity of the students and at that young
age, this unobtrusive security will eliminate the emotional experience of being
examined daily in their place of learning.
With the entrances and parking area and playground under video surveillance
the campus will be far more secure and prevent this sort of tragedy.
When Extract One hits the school market education will return to normal for those
schools. Until then even watching the news is alarming to us all.
Yes I am invested and for a very long time with this one!

I SEE what you are saying! True we have seen a very cautious and limited amount of excitement or push from CM, disappointing for sure. But all the studies and evidence indicate that Ifenprodil should be effective with Covid. The formal phase 2b/3 was to me an exploratory investigation to determine the best direction moving forward with their hands tied to the ethics of a scientific study. I believe this interim period allows AGN the company to narrow the focus, hence the scarring and oxygenation aspects can become a major focus moving forward, showing the real benefits of Ifenprodil on Covid patients.
Seems like a stretch to some I'm sure but this is my take at this point in time. The follow-up data release may give us a new approach to phase 3. The long haul Covid patients experiencing symptoms, including brain fog and mental issues, in my opinion should get significant relief if you consider some of the applications in Japan with Ifenprodil. For these reasons I remain very hopeful moving forward.
If you combine these potential benefits with another treatment with different benefits we should have the home-run we are all looking for!
My hope is CM can stay the course when meeting with the FDA to "
thread the needle!"
Thanks to M$S GVX808 and everyone for keeping us well informed

Sorry I was wrong about the 20mg 40 mg doses being the same. I contacted Mackie about the downgrade based on 40mg having no effect and was told it was a simple explanation, though he would not offer any explanation.
Once I heard CM on Facebook it became clear that 40mg was too high a dose and showed no effect.
Seems that Mackie knew more than us early on, and were giving a downgrade recommendation based on the weaker data, though seemingly ignoring the positive aspects of the data. hence the surprising SP drop.
So I am still in for some good prospects for phase 3 endpoints including long Covid patients. The dosage non issue to me simply implies that 20mg is enough to do the job, can be given early to patients showing symptoms, and should likely be continued after testing negative for a period of time for scarring...these are my hopes and AGN may save alot of misery if handled wisely. JMO
Great Share Price to buy more

Thank you GVX808 for quick research. I believe Mackie have made a huge error in interpreting the release as I read it. Here is what I think:
the study report stated quote:


"The Company investigated a 20 mg and 40 mg dose of Ifenprodil. Based on the initial data review, no significant changes were observed in the 40 mg dose group."

To me the "no significant changes" means there were nearly similar results for both the 20mg and 40mg doses, meaning a low dose does the lung repair , and there may not be a need for higher dosage at all. No changes to me means near similar results for both 20 and 40mg doses.

But Mackie have a different interpretation:

AGN disclosed 40 mg did not show any effects in this study while the 20 mg dose demonstrated some
trends. Based on the lack of dose response, we unfortunately would not expect this
indication to be advanced."

The "40 mg did not show any effects" part of this statement to me is inaccurate, the 40 mg had no significant changes from 20 mg. This led to the AGN share price dribbling to 25 cents seemingly as per their recommendation. I am shocked that this may become a serious issue.
Again thanks GVX808, I appreciate your comments and research and now follow you!

Results look great IMO, no mortality with low dose 20mg is worthy of a phase 3 study. The strongest endpoint seems to be oxygenation. levels quickly returning to normal(4 days vs 9 days) to me indicates the anti-scarring benefit of Ifenprodil is critical in treating patients who contract Covid 19, life saving capability.
I am excited to see which Big Pharma company jumps on this first!

found a lovely report on Yahoo by a reputable doctor we all know:

https://menafn.com/1101798548/The-Covid-19-Issue-Too-Many-Are-Ready-to-Overlook-and-the-Investing-Opportunity-It-Creates

Did you see beneath the 30 second video:
Algernon Pharmaceuticals Inc. (CSE: AGN) (OTCQB: AGNPF)

Algernon Pharmaceuticals is being featured on BNN Bloomberg on Feb 15th to 28th, 2021, throughout the day and evenings.
About BTV:

BTV-Business Television is Canada's longest running business show. With Hosts Taylor Thoen and Jessica Katrichak, BTV features emerging companies across the country to bring viewers investment opportunities. BTV also produces News Alerts and branding/awareness spots for issuers broadcast on BNN Bloomberg, Fox Business News, Bloomberg TV US and Bloomberg Terminals. www.b-tv.com

I feel the signal is weak because the dosing likely needs to be higher to have a positive result in such a short period of time. it may turn out that dosing when diagnosed will give ifenprodil time to do its work in preventing or at least reducing the harm caused by Covid 19. are they able to change phase 3 to look at such variants?

I am new to the board and appreciate all you do, have been and remain long and my primary goal has been the IPF study which I have confidence will succeed

how can there be such a huge spread on the board? It appears there may be a problem with the trading platform IMO

could you please stop the drama